Fig. 4
From: Proteomics of AML1/ETO Target Proteins: AML1–ETO Targets a C/EBP–NM23 Pathway
NM23 mRNA expression is increased in AML patient samples: a NM23 mRNA expression is increased in AML patient samples (n = 199) in comparison with normal bone marrow (nBM) mononuclear cells (n = 8). AML patient samples included FAB M2 patients with translocation t(8;21), M2 with normal karyotype (M2-NK), M2 with complex karyotype (M2-CK), M3 with t(15;17), M3 variants (M3v), M4eo inversion 16, t(11q23), AML complex karyotype, AML normal karyotype, normal karyotype with FLT+, and normal karyotype with MLL-PTD+. The error bars indicate the s.e.m.; n the number of patient samples analyzed in each subgroup. b HSP27 mRNA expression is also increased in AML patients which further validates the proteomics data